21 results about "Abiraterone" patented technology

The present disclosure relates to methods of treating PTEN-deficient metastatic hormone- sensitive prostate cancer (mHSPC) in patients in need thereof, the methods comprising administering to the patients a combination comprising capivasertib or a pharmaceutically acceptable salt thereof; and abiraterone or an ester prodrug thereof, or a pharmaceutically acceptable salt thereof.

The present disclosure relates to methods of treating prostate cancer in a subject comprising administering to the subject (a) an androgen receptor inhibitor and (b) an embryonic ectoderm development (EED) inhibitor, including those in which prostate cancer has been determined to be resistant to one or more androgen receptor signaling inhibitors (ARSIs), including (abiraterone).

The invention belongs to the technical field of crystal form drug molecules, and particularly relates to salts of abiraterone derivatives, in particular to glutarate of L-valine abiraterone. The glutarate of L-valine abiraterone provided by the invention has characteristic peaks at the positions of 8.2 + / -0.2 degrees, 8.9 + / -0.2 degrees, 9.9 + / -0.2 degrees, 16.5 + / -0.2 degrees, 17.0 + / -0.2 degrees, 17.8 + / -0.2 degrees and 19.8 + / -0.2 degrees in an X-ray diffraction spectrum represented by 2 theta. The glutarate has improved dissolution and dissolution performance, can play a therapeutic role more effectively, and is good in stability, small in adhesiveness and convenient to store and process.

The invention relates to the field of pharmaceutical preparations and pharmaceutical chemistry, belongs to the technical field of oral delivery of antitumor drugs, and particularly relates to an abiraterone lipophilic prodrug and application thereof. The prodrug meets the following general formula: AB-O-C (= O)-(CH2) m-S-S-(CH2) m-C (= O)-O-R, the prodrug significantly improves the fat solubility and intestinal absorption capacity of abiraterone, can be absorbed through a chylomicron-mediated lymph transport pathway, and releases a parent drug in a tumor cell high-reducibility environment. The SNEDDS preparation containing the prodrug can form a particle size of 1t in vivo; the O / W type nano emulsion droplet with the size of 100 nm can significantly improve the oral bioavailability of abiraterone and inhibit the growth of prostatic cancer tumors, and has a good application prospect.

The application discloses an abiraterone derivative and a preparation method thereof. The abiraterone derivative has a structure as shown in a general formula (I). The abiraterone derivative has high bioavailability and good tumor inhibition effect, and has a high drug prospect.

The present disclosure relates to a combination of abiraterone acetate and niraparib, free-dose and fixed-dose combinations of abiraterone acetate and niraparib, and methods of treatment of prostate cancer with said combinations.

The present application relates to the technical field of pharmaceutical preparation, and in particular to an abiraterone acetate enteric microcapsule and a preparation method thereof. The present application uses an emulsion diffusion method to prepare abiraterone acetate nanocapsules, then uses an enteric material to load the abiraterone acetate nanocapsules, and finally uses a spray drying technology to prepare abiraterone acetate oral enteric microcapsules. Through pharmacokinetic tests of a rat chylomicron blocking model, it is verified that the abiraterone acetate enteric microcapsules prepared by the present application are absorbed by the lymphatic pathway in the small intestine, so it is proved that the present application can enhance the permeability and solubility of abiraterone acetate in the body, improve the oral bioavailability thereof in the body, the preparation method is simple and controllable, has good repeatability, the particle size of the prepared nanocapsules is 182.3±5.7 nm, the Zeta potential is-15.0±1.1 mV, and the encapsulation rate is 92.4±1.7%.

The invention discloses an abiraterone borane carrying agent with prostatic cancer targeting property as well as a preparation method and application of the abiraterone borane carrying agent. The abiraterone borane compound comprises abiraterone borane and abiraterone acetate borane. According to the embodiment of the invention, based on abiraterone acetate and prostatic cancer targeting and safety of abiraterone, a borane group is introduced into structures of abiraterone acetate and abiraterone acetate, and a novel boron carrying agent is obtained and is used for BNCT treatment of prostatic cancer. The novel boron carrying agent not only retains the CYP17 enzyme inhibitory activity of abiraterone and abiraterone acetate, but also provides the possibility of targeting prostate cancer cells for BNCT by introducing a 10B isotope. Through the innovative medicine design, the curative effect and selectivity of BNCT in prostatic cancer treatment can be remarkably improved, damage to normal tissue is reduced, and a safer and more effective treatment choice is provided for prostatic cancer patients.

Disclosed in the present invention are an abiraterone derivative, a pharmaceutical composition, and a preparation method therefor and the use thereof. Provided in the present invention is an abiraterone derivative as represented by formula (1) or formula (2), or a pharmaceutically acceptable salt thereof. In contrast to existing abiraterone derivative structures in which each molecule contains one abiraterone molecule, the compound of the present invention contains two abiraterone molecules per molecule. The compound of the present invention has long-acting sustained-release characteristics, can be injected subcutaneously or intramuscularly, maintains the blood drug level for 12 weeks (3 months) or longer, and is used for treating prostate cancer.

The invention belongs to the technical field of crystal form medicine molecules, and particularly relates to a p-toluenesulfonic acid crystal form of L-valine abiraterone and a preparation method of the p-toluenesulfonic acid crystal form. In the p-toluenesulfonic acid crystal form of L-valine abiraterone provided by the invention, the molar ratio of L-valine abiraterone to p-toluenesulfonic acid to water is 1: 1: 2, and an X-ray diffraction pattern represented by 2 theta has characteristic peaks at the positions of 11.9 + / -0.2 degrees, 12.9 + / -0.2 degrees, 15.4 + / -0.2 degrees, 17.5 + / -0.2 degrees and 21.5 + / -0.2 degrees. The obtained crystal form has improved stability, solubility and flowing property, is suitable for manufacturing and application of pharmaceutical preparations, and is expected to promote design of abiraterone preparations and clinical application.

The invention provides a temperature-sensitive hydrogel for prostate local drug delivery and a preparation method thereof. The core components of the temperature-sensitive hydrogel comprise a temperature-sensitive carrier compounded by a polylactic acid-glycolic acid-polyethylene glycol triblock copolymer and modified chitosan, targeted active components such as abiraterone and the like and a composite bacteriostatic agent, and a biological adhesion and transdermal enhancer is added; the hydrogel is a sol at normal temperature, is convenient for administration, is rapidly gelatinized at 35-37 DEG C to realize local retention, has excellent biological adhesion and antibacterial properties, is stable and long-acting in drug release, and has an accumulative release rate of 86-92% in 96 h. The preparation process is stable and controllable, is suitable for treating diseases such as prostatic cancer and prostatitis, can improve the bioavailability of drugs and reduce side effects, and has important clinical application value.

The present disclosure relates to a pharmaceutical product having at least one batch indication, wherein the pharmaceutical product comprises niraparib and abiraterone acetate.

A drug composition containing abiraterone acetate, and a preparation method therefor and an application thereof. Excipients thereof comprise at least one oil phase, at least one emulsifier, and at least one co-emulsifier. The dug composition can obviously improve the bioavailability and the stability of a preparation. The drug composition can be further prepared as capsules.

Sustained-release abiraterone prodrug formulations, methods, and kits for parenteral administration to a subject having a sex hormone-dependent benign or malignant disorder such as prostate cancer, an androgen receptor driven cancer, a syndrome due to androgen excess, and / or a syndrome due to glucocorticoid excess such as hypercortisolemia.

This disclosure relates to a combination of abiraterone acetate and niraparib, to free-dose and fixed-dose combinations of abiraterone acetate and niraparib, and to methods of treating prostate cancer with such combinations.

The application discloses an abiraterone derivative, a pharmaceutical composition and a preparation method and application thereof. The application provides an abiraterone derivative as shown in formula (1) or formula (2), or a pharmaceutically acceptable salt thereof, which is different from an existing abiraterone derivative structure and contains one abiraterone molecule per molecule; the compound of the application contains two abiraterone molecules per molecule. The compound of the application has a long-acting slow-release feature, can be injected subcutaneously or intramuscularly, maintains a blood drug concentration for 12 weeks (3 months) or more, and is used for the treatment of prostate cancer.

The invention discloses a gene marker combination for predicting the curative effect of abiraterone in metastatic castration resistant prostate cancer (mCRPC). The gene marker combination comprises 16 genes, namely HDAC2, TP53, GEN1, FOXA1, ATR, MUTYH, SPOP, BRCA2, ATM, PALB2, RB1, CDK12, BARD1, PTEN, NCOR2 and MLH1. The invention further discloses an mCRPC abiraterone curative effect prediction model based on the marker combination and a construction method of the mCRPC abiraterone curative effect prediction model. According to the method, mCRPC gene markers highly related to abiraterone treatment response are screened based on detection data of related genes of prostate cancer in combination with clinical abiraterone treatment effect results, and an abiraterone treatment effect prediction model is constructed based on the markers, so that personalized prediction of the treatment effect of an mCRPC patient using abiraterone treatment is realized, and the treatment effect of the patient is improved. And an effective reference can be provided for accurate medication.

The invention discloses a low-cost abiraterone synthesis method, and relates to the technical field of medicine preparation, and the method comprises the following steps: (1) preparing an organic zinc reagent: adding an inorganic catalyst, an initiator, zinc powder or zinc chloride into an aprotic polar solvent, and dropwise adding 3-bromopyridine to obtain the organic zinc reagent; (2) synthesizing an intermediate: adding the intermediate III, a metal catalyst and a ligand into an aprotic polar solvent, dropwise adding an organic zinc reagent, and carrying out a coupling reaction at a certain temperature to obtain an intermediate II; (3) mixing and stirring the intermediate II and a hydrochloric acid aqueous solution for deprotection, filtering and purifying to obtain abiraterone; the method has the advantages of low preparation cost, high yield, high purity and the like.

The invention relates to the technical field of drug detection, and discloses a method for detecting beta-lactam compound residues in a drug, which comprises the following steps of: extracting and diluting beta-lactam compounds in the drug through a uniform pretreatment process (adopting 50% acetonitrile) in combination with optimized LC-MS / MS conditions (including specific chromatographic columns, gradient elution procedures and mass spectrum parameters); synchronous quantitative detection of eight beta-lactam compounds (covering cephalosporin and penem) in five raw material medicines (exemestane, etoposide, abiraterone acetate, emtricitinib and cilnimod) with remarkable structural difference is realized, and the limit of quantitation is as low as 0.008 ppm. According to the method, the detection sensitivity is remarkably improved, the trace residue monitoring requirement is met, pretreatment steps are simple and universal, conditions do not need to be adjusted according to different raw material medicines, the detection efficiency and the method applicability are greatly improved, and the problems that the sensitivity is insufficient and the universality is poor in the prior art are effectively solved.